Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions
Geographic Atrophy
Interventions
DRUG

ORACEA®

ORACEA® (40mg doxycycline) capsule daily for 24 months

DRUG

Placebo

Placebo capsule daily for 24 months

Trial Locations (37)

10021

MaculaCare, New York

10022

Vitreous Retina Macula Consultants of New York, New York

14620

Retina Associates of Western New York, Rochester

15122

Associates in Ophthalmology, Ltd, West Mifflin

15213

University of Pittsburgh Eye Center, Pittsburgh

17011

Pennsylvania Retina Specialists, PC, Camp Hill

19107

Mid Atlantic Retina / Wills Eye Institute, Philadelphia

20037

George Washington University, Washington D.C.

20186

Virginia Retina Center, Warrenton

22903

University of Virginia, Charlottesville

23462

Wagner Macula & Retina Center, Virginia Beach

25301

Retina Cosultants, Charleston

32514

Medical Center Eye Institute / Gulf Region Clinical Research Institute, Pensacola

33308

Retina Group of Florida, Fort Lauderdale

33703

Retina Vitreous Associates of Florida, St. Petersburg

40509

Retina Associates of Kentucky, Lexington

44195

Cole Eye Institute / Cleveland Clinic Foundation, Cleveland

49525

Retina Specialists of Michigan, Grand Rapids

55404

Retina Center, Minneapolis

61704

Gailey Eye Clinic, Bloomington

63017

Lifelong Vision Foundation, Chesterfield

78240

Retina Associates of South Texas, San Antonio

78705

Brian B. Berger, MD and Associates / Retina Research Center, Austin

79606

Retina Research Institute of Texas, Abilene

80027

Eldorado Retina Associates, Louisville

80401

Colorado Retina Associates, PC, Golden

91203

Macula and Retina Institute, Glendale

92064

Retina Consultants of San Diego, Poway

97401

Oregon Retina, Eugene

06518

New England Retina Associates, Hamden

02111

New England Eye Center at Tufts Medical Center, Boston

02215

Harvard Vanguard Medical Associates, Boston

01605

Vitreo-Retinal Associates, Worcester

08648

Delaware Valley Retina Associates, Lawrenceville

08225

Retinal and Ophthalmic Consultants, Northfield

08755

New Jersey Retina, Toms River

Unknown

New York Eye and Ear, New York

All Listed Sponsors
collaborator

MEDARVA Foundation

UNKNOWN

lead

Paul Yates, MD, PhD

OTHER

NCT01782989 - Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) | Biotech Hunter | Biotech Hunter